Australia

How Have HTA Agencies Evolved Their Methods Over Time?

29 April 2024

The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.

Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report

18 April 2024

Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

18 September 2023

In this report, we explore the potential impact of the National Institute of Health and Care Excellence (NICE) decision outcomes on healthcare decision-making in 12 countries across the globe (Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab Emirates). We used quantitative and qualitative methods to estimate the level of impact and potential underlying mechanisms.

Are Recommendations for HTA of Gene Therapies Being Achieved?

11 September 2023

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.

Combination Therapies: A Step Forward to the Value Attribution Problem

4 January 2023

OHE convened a roundtable discussion to present and discuss recent work by OHE colleagues and collaborators on value attribution frameworks for combination therapies.

Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

1 February 2021

This research paper examines whether value of a life estimates used in economic evaluation differs between government departments in a selection of developed countries. The authors find that generally estimates used in transport and the environment exceeded those used in health, which suggests that health may be undervalued by departments of health compared to departments of transport or environment.

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

5 January 2020

OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs).…

The Publicly Funded Vaccines Market in Australia

1 October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how…

Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?

1 May 1997

Getting value for money from the use of pharmaceuticals is crucial for the NHS. This publication explores the role for guidelines in generating good quality value…